Vir Biotechnology and Alnylam Pharmaceuticals Initiate Phase 1/2 Study of VIR-2218
Alnylam Pharmaceuticals, Inc. (ALNY)
Last alnylam pharmaceuticals, inc. earnings: 2/6 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.alnylam.com/investor-overview
Company Research
Source: Business Wire
-- Novel investigational RNAi therapeutic for the treatment of chronic hepatitis B virus (HBV) infection -- Subject dosing commenced SAN FRANCISCO & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vir Biotechnology, Inc. and Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) today announced the initiation of a Phase 1/2 study of VIR-2218, a novel, investigational RNA interference (RNAi) therapeutic for the treatment of chronic hepatitis B virus (HBV) infection. The commencement of first-in-human dosing marks the first clinical use of Alnylam’s Enhanced Stabilization Chemistry-Plus (ESC+) GalNAc conjugate delivery platform and the start of Vir’s first global development program. VIR-2218 was originated by Alnylam as ALN-HBV02 and was licensed to Vir, which will conduct its clinical development. “Almost one-third of the world's population have current or previous hepatitis B infection, which is the leading c
Show less
Read more
Impact Snapshot
Event Time:
ALNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALNY alerts
High impacting Alnylam Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ALNY
News
- Pfizer nabs first obesity approval; Alnylam, Tenaya search for heart drugs [Yahoo! Finance]Yahoo! Finance
- Alnylam and Tenaya sign $1.23bn cardiovascular target discovery deal [Yahoo! Finance]Yahoo! Finance
- Tenaya Therapeutics inks $1.13 billion deal with Alnylam for heart-disease treatments [Yahoo! Finance]Yahoo! Finance
- Helix Announces Multi-Year Agreement with Alnylam to Drive Precision Medicine Development [Yahoo! Finance]Yahoo! Finance
- Alnylam's research pact worth up to $1.1B sends Tenaya higher [Seeking Alpha]Seeking Alpha
ALNY
Earnings
- 2/12/26 - Beat
ALNY
Sec Filings
- 3/6/26 - Form 4
- 3/6/26 - Form 4
- 3/6/26 - Form 4
- ALNY's page on the SEC website